TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03801174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner-assisted intervention
Description: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient-only intervention
Description: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
Study: NCT03162822

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Intervention
Description: The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interpretation Bias Intervention
Description: The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluative Conditioning
Description: The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
Study: NCT01086774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Ultra Lubricant Eye Drops
Description: Single drop in both eyes
Study: NCT02742220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Handgrip Training Group
Description: Intervention period will last eight weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of four unilateral sets (dominant arm) with two minutes of isometric contraction, with 30% of maximum voluntary contraction, and four minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. Visits will be scheduled at weeks 1 and 5 to provide feedback to individuals, discuss possible problems during the training and adjust the intensity of the exercise. In addition the patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Intervention period will last eight weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
Study: NCT04199429

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relationship-Based Care
Study: NCT01008059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: No drug treatment before alfentanil
Study: NCT04199429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relationship-Based Care
Study: NCT01715506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: The educational intervention (EI), Relation Related Care (RRC), consists of a two-day seminar and one hour monthly guidance for six months. Course material, a book particularly designed for this intervention and dealing with person centered care and use of restraint, is distributed ahead of the course part of the intervention to all participants.
Study: NCT02090452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real time transmission of patient related data. Device used: MobiMed 3.1, manufactured by Ortivus AB Sweden
Study: NCT00270400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide
Study: NCT01362231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6624
Description: Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6624
Description: Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
Study: NCT04198974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PreVenture Training (PTtT)
Description: PreVenture TtT model will involve identifying local expert trainers to be trained to train school-based professionals on the PreVenture program. Steps include:~1. PreVenture Facilitator certification: Trainers participate in training workshops and deliver the program to eligible youth in Cohort 1 and are rated on quality of implementation using the PIFA.~2. Reliable use of the PIFA: Each trainer demonstrates convergence with the Montreal Team's ratings on a set of previously-recorded PreVenture sessions.~3. PreVenture Training Workshop Certification: Trainers participate in a one-day TtT workshop to review the main aims and exercises of PreVenture Training. Trainers then record mock TtT sessions in which key components of the PreVenture Training Workshop are delivered to an audience of 4-10 individuals (e.g., class of graduate students). These sessions are rated by the Montreal Team the PreVenture Implementation Fidelity and Adherence-Trainer Scale (PIFA-T).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PreVenture Training+Implementation Facilitation
Description: PreVenture TtT model + Implementation Facilitation Package:~1. Youth advisors identified the role of older youth to support program implementation. Youth will help promote PreVenture to students and families and help Facilitators optimize attendance at sessions.~2. Trainer-led coaching sessions will focus on enhancing program fidelity and acceptability by Facilitators. 'Best practice' supervision elements from efficacy trials will be integrated. Fidelity and symptom monitoring will be conducted in real-time during program implementation.~3. Performance metrics have been developed based on youth qualitative feedback to PreVenture sessions in previous trials. Analysis indicates key responses that are predictive of students most likely to benefit from PreVenture on 12-month substance use outcomes and indicates the extent to which Facilitator's interventions are leaving students with impressions consistent with positive long-term outcomes.
Study: NCT01619709

Intervention type: OTHER
Group type: OTHER
Intervention: Pet AV-45
Description: AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.

Intervention type: OTHER
Group type: OTHER
Intervention: Pet AV-45
Description: AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
Study: NCT03267199

Intervention type: DRUG
Intervention: Thrombolytic
Description: Thrombolytic therapy

Intervention type: DRUG
Intervention: Thrombolytic
Description: Thrombolytic therapy

Intervention type: PROCEDURE
Intervention: Primary PCI
Description: Primary percutaneous coronary intervention
Study: NCT03852316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Click Device
Description: A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
Study: NCT03050905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEKIRAX
Description: Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).~Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXVIERA
Description: Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Dasabuvir (Exviera).~Study Regimen: dasabuvir (250 mg twice daily)
Study: NCT03267199

Intervention type: PROCEDURE
Intervention: Primary PCI
Description: Primary percutaneous coronary intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: Blood sample for complete blood count

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: Blood sample for complete blood count

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet function test
Description: Blood sample for platelet function test

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet function test
Description: Blood sample for platelet function test

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: Electrocardiogram

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: Electrocardiogram
Study: NCT02991911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI3726 Post-Chemo
Description: Single agent MEDI3726 after abiraterone or enzalutatmide, with a prior taxane-based chemotherapy in the mCRPC setting

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI3726 Pre-Chemo
Description: Single agent MEDI3726 after abiraterone or enzalutatmide, without a prior taxane-based chemotherapy in the mCRPC setting

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI3726 & Enzalutamide Combo
Description: MEDI3726 in combination with Enzalutatmide after prior treatment with abiraterone, with or without a prior taxane-based chemotherapy in the mCRPC setting
Study: NCT02279602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosbretabulin
Description: fosbretabullin, 60 mg/m2 weekly for up to 1 year
Study: NCT00588120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-13 labeled oxalate
Description: A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.~Take one capsule by mouth for one day.
Study: NCT04218058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reduction of zygomatic arch in zygomaticomaxillary complex fracture
Description: ultrasound guided reduction of zygomatic arch

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reduction of zygomatic arch in zygomaticomaxillary complex fracture
Description: ultrasound guided reduction of zygomatic arch
Study: NCT01091792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab every 2 weeks 10mg/kg beginning 2 weeks after start of Radiation Therapy
Study: NCT03081585

Intervention type: BEHAVIORAL
Intervention: Satiety State
Description: Participants were scanned twice: once after a meal and once after fasting for 24 hours
Study: NCT01161329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Exercise Programmes (HIFE)
Description: Hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. All exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. HIFE are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. Two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. The exercises will be progressively increased in load and difficulty.
Study: NCT00810953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine
Description: two dose of 6 mg/kg with or without standard chemotherapy.
Study: NCT04173143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Craniocervical flexion training with pressure biofeedback
Description: Total 15 patients participated in this training group. Session was performed thrice in a week. Each session was givenfor approximately 20minutesPatients were asked to lie in supine hook lying position. After that Pressure biofeedback unit's air bag was clipped together and folded in three and positioned behind the neck just below the occiput. Patients were advised to perform Craniocervical flexion and practiced head nodding action to progressively target (reach the incremental targets) and hold the 5 pressure levels for 10 second between 22 mm Hg and 30 mmHg. A 2 minute second rest period was provided between each level. Minimum performance requirement was 26 mm Hg while ideal performance targets are 28 and 30 mm Hg... Patient will be re-assessed for all baseline variables after 4 weeks of training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Craniocervical flexion training without pressure biofeedback
Description: Total 15 patients participated in this control group.Session was given 3 times in a week. Each session continue forapproximately 20 minutes. The patient lies in supine crook lying position. The patientwas maximally retracted the chin and asked to maintained it while the patient lifts the head and neck until the head is relatively 2 to 5 cm (1 inch) abovethe couch. The examiner places a hand under the head of patient on the table. Patients were instructed to perform10 repetitions for a hold of 20 seconds initially, increasing it by 10 seconds progressively.The entire session had a maximum of 4 sets. Patient will be re-assessed for all baseline variables after 4 weeks of training
Study: NCT00735371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDX 30 mg
Description: Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDX 50 mg
Description: Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDX 70 mg
Description: Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical to test product.
Study: NCT03582488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Flortaucipir
Description: Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
Study: NCT00395239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled corticosteroid
Description: Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
Study: NCT05665257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mini-PEP
Study: NCT02352831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tosedostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tosedostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fresh tissue biopsy
Description: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fresh tissue biopsy
Description: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
Study: NCT03494452

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this cross-sectional study

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this cross-sectional study
Study: NCT03800121

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Localized sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample before surgery (32 ml) + 1 blood sample 1 month after surgery (32 ml) + 1 blood sample 3 month after surgery (32 ml) + 1 blood sample 6 month after surgery (32 ml)~Metastatic sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample during chemotherapy cure 1 (32 ml) + 1 blood sample during chemotherapy cure 3 (32 ml) + 1 blood sample during chemotherapy cure 6 (32 ml)

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Localized sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample before surgery (32 ml) + 1 blood sample 1 month after surgery (32 ml) + 1 blood sample 3 month after surgery (32 ml) + 1 blood sample 6 month after surgery (32 ml)~Metastatic sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample during chemotherapy cure 1 (32 ml) + 1 blood sample during chemotherapy cure 3 (32 ml) + 1 blood sample during chemotherapy cure 6 (32 ml)
Study: NCT03531086

Intervention type: DRUG
Intervention: Ioflupane I 123
Description: Ioflupane I 123 will be administered IV push prior to SPECT imaging
Study: NCT01526213

Intervention type: DRUG
Group type: OTHER
Intervention: Fexofenadine
Description: This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.

Intervention type: DRUG
Group type: OTHER
Intervention: Fexofenadine
Description: This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.

Intervention type: DRUG
Group type: OTHER
Intervention: Fexofenadine
Description: This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.

Intervention type: DRUG
Group type: OTHER
Intervention: Fexofenadine
Description: This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.

Intervention type: DRUG
Group type: OTHER
Intervention: Fexofenadine
Description: This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.
Study: NCT03738046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, \& Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, \& Wykes, 2016).
Study: NCT00124917

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Areas of pathologically confirmed malignancy will undergo dose escalation as described below. Areas of image abnormality that could not be biopsied or were without definite pathologic evidence of malignancy will be given intermediate doses. The remainder of the prostate gland will receive standard dose (as per the Radiation Therapy Oncology Group (RTOG) 9406 study) 7560 centigray (cGy) in 180 cGy daily fractions.\[1\]
Study: NCT03648229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Description: Delivery of laser energy to the trabecular meshwork of the eye with the goal of reducing intraocular pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Description: Prostaglandin analogue topical ophthalmic medication for reduction of intraocular pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Description: Prostaglandin analogue topical ophthalmic medication for reduction of intraocular pressure
Study: NCT01526213

Intervention type: DRUG
Group type: OTHER
Intervention: Fexofenadine
Description: This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.